1 Introduction to Research & Analysis Reports
1.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Overall Market Size
2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size: 2022 VS 2029
2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales: 2018-2029
3 Company Landscape
3.1 Top Tumor Necrosis Factor Receptor Superfamily Member 18 Players in Global Market
3.2 Top Global Tumor Necrosis Factor Receptor Superfamily Member 18 Companies Ranked by Revenue
3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Companies
3.4 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Companies
3.5 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Tumor Necrosis Factor Receptor Superfamily Member 18 Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Tumor Necrosis Factor Receptor Superfamily Member 18 Product Type
3.8 Tier 1, Tier 2 and Tier 3 Tumor Necrosis Factor Receptor Superfamily Member 18 Players in Global Market
3.8.1 List of Global Tier 1 Tumor Necrosis Factor Receptor Superfamily Member 18 Companies
3.8.2 List of Global Tier 2 and Tier 3 Tumor Necrosis Factor Receptor Superfamily Member 18 Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size Markets, 2022 & 2029
4.1.2 AMG-228
4.1.3 BMS-986156
4.1.4 FPA-154
4.1.5 GWN-323
4.1.6 INCAGN-1876
4.1.7 Others
4.2 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue & Forecasts
4.2.1 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2023
4.2.2 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2024-2029
4.2.3 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
4.3 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales & Forecasts
4.3.1 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2018-2023
4.3.2 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2024-2029
4.3.3 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
4.4 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2022 & 2029
5.1.2 Melanoma
5.1.3 Non-Small Cell Lung Cancer
5.1.4 Gastric Cancer
5.1.5 Blood Cancer
5.1.6 Others
5.2 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue & Forecasts
5.2.1 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2023
5.2.2 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2024-2029
5.2.3 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
5.3 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales & Forecasts
5.3.1 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2018-2023
5.3.2 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2024-2029
5.3.3 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
5.4 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2022 & 2029
6.2 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue & Forecasts
6.2.1 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2023
6.2.2 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2024-2029
6.2.3 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
6.3 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales & Forecasts
6.3.1 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2018-2023
6.3.2 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2024-2029
6.3.3 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2029
6.4.2 By Country – North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2018-2029
6.4.3 US Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.4.4 Canada Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.4.5 Mexico Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2029
6.5.2 By Country – Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2018-2029
6.5.3 Germany Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.5.4 France Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.5.5 U.K. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.5.6 Italy Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.5.7 Russia Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.5.8 Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.5.9 Benelux Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2029
6.6.2 By Region – Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2018-2029
6.6.3 China Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.6.4 Japan Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.6.5 South Korea Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.6.6 Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.6.7 India Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2029
6.7.2 By Country – South America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2018-2029
6.7.3 Brazil Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.7.4 Argentina Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, 2018-2029
6.8.3 Turkey Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.8.4 Israel Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.8.5 Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
6.8.6 UAE Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Ablynx NV
7.1.1 Ablynx NV Company Summary
7.1.2 Ablynx NV Business Overview
7.1.3 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.1.4 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.1.5 Ablynx NV Key News & Latest Developments
7.2 Amgen Inc
7.2.1 Amgen Inc Company Summary
7.2.2 Amgen Inc Business Overview
7.2.3 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.2.4 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.2.5 Amgen Inc Key News & Latest Developments
7.3 Apogenix GmbH
7.3.1 Apogenix GmbH Company Summary
7.3.2 Apogenix GmbH Business Overview
7.3.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.3.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.3.5 Apogenix GmbH Key News & Latest Developments
7.4 Bristol-Myers Squibb Company
7.4.1 Bristol-Myers Squibb Company Company Summary
7.4.2 Bristol-Myers Squibb Company Business Overview
7.4.3 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.4.4 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.4.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.5 Five Prime Therapeutics Inc
7.5.1 Five Prime Therapeutics Inc Company Summary
7.5.2 Five Prime Therapeutics Inc Business Overview
7.5.3 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.5.4 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.5.5 Five Prime Therapeutics Inc Key News & Latest Developments
7.6 Incyte Corp
7.6.1 Incyte Corp Company Summary
7.6.2 Incyte Corp Business Overview
7.6.3 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.6.4 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.6.5 Incyte Corp Key News & Latest Developments
7.7 MedImmune LLC
7.7.1 MedImmune LLC Company Summary
7.7.2 MedImmune LLC Business Overview
7.7.3 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.7.4 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.7.5 MedImmune LLC Key News & Latest Developments
7.8 Merck & Co Inc
7.8.1 Merck & Co Inc Company Summary
7.8.2 Merck & Co Inc Business Overview
7.8.3 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.8.4 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.8.5 Merck & Co Inc Key News & Latest Developments
7.9 Novartis AG
7.9.1 Novartis AG Company Summary
7.9.2 Novartis AG Business Overview
7.9.3 Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.9.4 Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.9.5 Novartis AG Key News & Latest Developments
7.10 OncoMed Pharmaceuticals Inc
7.10.1 OncoMed Pharmaceuticals Inc Company Summary
7.10.2 OncoMed Pharmaceuticals Inc Business Overview
7.10.3 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.10.4 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.10.5 OncoMed Pharmaceuticals Inc Key News & Latest Developments
7.11 Regeneron Pharmaceuticals Inc
7.11.1 Regeneron Pharmaceuticals Inc Company Summary
7.11.2 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Overview
7.11.3 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Major Product Offerings
7.11.4 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Revenue in Global (2018-2023)
7.11.5 Regeneron Pharmaceuticals Inc Key News & Latest Developments
8 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Production Capacity, Analysis
8.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Production Capacity, 2018-2029
8.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Production Capacity of Key Manufacturers in Global Market
8.3 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Tumor Necrosis Factor Receptor Superfamily Member 18 Supply Chain Analysis
10.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Industry Value Chain
10.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Upstream Market
10.3 Tumor Necrosis Factor Receptor Superfamily Member 18 Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Table 1. Key Players of Tumor Necrosis Factor Receptor Superfamily Member 18 in Global Market
Table 2. Top Tumor Necrosis Factor Receptor Superfamily Member 18 Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Share by Companies, 2018-2023
Table 5. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Tumor Necrosis Factor Receptor Superfamily Member 18 Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Tumor Necrosis Factor Receptor Superfamily Member 18 Product Type
Table 9. List of Global Tier 1 Tumor Necrosis Factor Receptor Superfamily Member 18 Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Tumor Necrosis Factor Receptor Superfamily Member 18 Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), 2018-2023
Table 15. By Type - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), 2024-2029
Table 16. By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), 2018-2023
Table 20. By Application - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), 2024-2029
Table 21. By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), 2018-2023
Table 25. By Region - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), 2024-2029
Table 26. By Country - North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2024-2029
Table 30. By Country - Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2024-2029
Table 34. By Region - Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2024-2029
Table 38. By Country - South America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2024-2029
Table 42. By Country - Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, (K Pcs), 2024-2029
Table 46. Ablynx NV Company Summary
Table 47. Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 48. Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Ablynx NV Key News & Latest Developments
Table 50. Amgen Inc Company Summary
Table 51. Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 52. Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Amgen Inc Key News & Latest Developments
Table 54. Apogenix GmbH Company Summary
Table 55. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 56. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Apogenix GmbH Key News & Latest Developments
Table 58. Bristol-Myers Squibb Company Company Summary
Table 59. Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 60. Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Bristol-Myers Squibb Company Key News & Latest Developments
Table 62. Five Prime Therapeutics Inc Company Summary
Table 63. Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 64. Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Five Prime Therapeutics Inc Key News & Latest Developments
Table 66. Incyte Corp Company Summary
Table 67. Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 68. Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Incyte Corp Key News & Latest Developments
Table 70. MedImmune LLC Company Summary
Table 71. MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 72. MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. MedImmune LLC Key News & Latest Developments
Table 74. Merck & Co Inc Company Summary
Table 75. Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 76. Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. Merck & Co Inc Key News & Latest Developments
Table 78. Novartis AG Company Summary
Table 79. Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 80. Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. Novartis AG Key News & Latest Developments
Table 82. OncoMed Pharmaceuticals Inc Company Summary
Table 83. OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 84. OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. OncoMed Pharmaceuticals Inc Key News & Latest Developments
Table 86. Regeneron Pharmaceuticals Inc Company Summary
Table 87. Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Product Offerings
Table 88. Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. Regeneron Pharmaceuticals Inc Key News & Latest Developments
Table 90. Tumor Necrosis Factor Receptor Superfamily Member 18 Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 91. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Production by Region, 2018-2023 (K Pcs)
Table 93. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Production by Region, 2024-2029 (K Pcs)
Table 94. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Opportunities & Trends in Global Market
Table 95. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Drivers in Global Market
Table 96. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Restraints in Global Market
Table 97. Tumor Necrosis Factor Receptor Superfamily Member 18 Raw Materials
Table 98. Tumor Necrosis Factor Receptor Superfamily Member 18 Raw Materials Suppliers in Global Market
Table 99. Typical Tumor Necrosis Factor Receptor Superfamily Member 18 Downstream
Table 100. Tumor Necrosis Factor Receptor Superfamily Member 18 Downstream Clients in Global Market
Table 101. Tumor Necrosis Factor Receptor Superfamily Member 18 Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Tumor Necrosis Factor Receptor Superfamily Member 18 Segment by Type in 2022
Figure 2. Tumor Necrosis Factor Receptor Superfamily Member 18 Segment by Application in 2022
Figure 3. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, 2018-2029 (US$, Mn)
Figure 7. Tumor Necrosis Factor Receptor Superfamily Member 18 Sales in Global Market: 2018-2029 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue in 2022
Figure 9. By Type - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
Figure 11. By Type - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
Figure 12. By Type - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price (USD/Pcs), 2018-2029
Figure 13. By Application - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
Figure 15. By Application - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
Figure 16. By Application - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Price (USD/Pcs), 2018-2029
Figure 17. By Region - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
Figure 20. By Region - Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
Figure 21. By Country - North America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
Figure 22. By Country - North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
Figure 23. US Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
Figure 28. Germany Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 29. France Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
Figure 37. China Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 41. India Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
Figure 43. By Country - South America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
Figure 44. Brazil Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share, 2018-2029
Figure 48. Turkey Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue, (US$, Mn), 2018-2029
Figure 52. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Production Capacity (K Pcs), 2018-2029
Figure 53. The Percentage of Production Tumor Necrosis Factor Receptor Superfamily Member 18 by Region, 2022 VS 2029
Figure 54. Tumor Necrosis Factor Receptor Superfamily Member 18 Industry Value Chain
Figure 55. Marketing Channels
※参考情報 腫瘍壊死因子受容体スーパーファミリーメンバー18(TNFRSF18)は、腫瘍壊死因子受容体スーパーファミリーに属する重要な受容体であり、免疫系の調節に寄与する重要な役割を果たしています。この受容体は、特にT細胞やB細胞を含む多くの免疫細胞に発現しており、細胞間の相互作用やシグナル伝達に関与しています。 まず、腫瘍壊死因子受容体スーパーファミリーメンバー18の機能について考察します。TNFRSF18は、主に「GITR」(Glucocorticoid-Inducible TNFR-Related Protein)と呼ばれる名前でも知られています。この受容体は、免疫抑制的なマイクロ環境を持つ腫瘍において特に重要性が増すことがわかっています。GITRの活性化は、T細胞の活性化や増殖を促進し、免疫応答を強化する効果があることが示されています。 次に、TNFRSF18の構造的な特徴について述べます。TNFRSF18は、通常の腫瘍壊死因子受容体の構造を持ち、細胞膜に埋め込まれたトランスメンブレインドメインを持っています。その外部領域は、リガンドとの結合に関与し、内部にシグナル伝達ドメインを持ち、受容体が活性化されると、細胞内のシグナル伝達経路が開始されます。この経路には、NF-κBやAP-1などの転写因子が関与しており、これにより免疫応答や細胞の生存が調節されます。 TNFRSF18は、主に2つのリガンドに結合します。一つは、GITRリガンド(GITRL)であり、もう一つはTNFファミリーの他のメンバーです。GITRLは、GITRとの結合を通じてT細胞の活性化を促進し、結果的に免疫応答を強化する役割を担っています。また、GITRの発現は、特定のリンパ球のサブセットにおいても増加することが知られており、特に調節的T細胞(Treg)との相互作用にも関与しています。 TNFRSF18は、さまざまな種類の細胞に発現していますが、特にT細胞における役割が注目されています。GITRは、T細胞の活性化や増殖、さらには耐性獲得などに関与しており、これががん治療や自己免疫疾患の治療において重要な一因となっています。また、腫瘍微小環境においても、GITRは腫瘍に対する抗腫瘍免疫応答を促進するための重要なターゲットとされています。 さらに、腫瘍壊死因子受容体スーパーファミリーメンバー18は、研究や医療分野においてさまざまな用途が検討されています。その一つは、がん免疫療法における応用です。近年、GITRをターゲットにした抗体薬や細胞治療が開発され、腫瘍に対する免疫応答を增强するための戦略が試みられています。特に、GITRの活性化は、腫瘍に対するT細胞の効果的な応答を引き出す可能性があり、これががん治療の新しいアプローチとして注目されています。 また、自己免疫疾患においてもTNFRSF18の役割が考慮されています。GITRに関連する経路は、自己免疫疾患の進行に関与しているとされ、GITRをターゲットとする治療法は、これらの疾患の制御や予防に向けた新たな可能性を提供しています。T細胞の調節機能を高めることによって、自己免疫反応を抑制し、疾患の進行を抑えることが期待されています。 さらに、腫瘍壊死因子受容体スーパーファミリーメンバー18に関連する技術的進展も注目されています。バイオテクノロジーや分子生物学の進歩により、この受容体をターゲットとする新しい分子や薬剤が次々と開発されています。特に、モノクローナル抗体を用いた治療法や、CAR-T細胞療法(Chimeric Antigen Receptor T-cell therapy)におけるGITRの組み込みが進められています。これらの技術は、がんや自己免疫疾患の治療に革新をもたらす可能性があると期待されます。 最後に、腫瘍壊死因子受容体スーパーファミリーメンバー18の今後の研究の方向性についても考察する必要があります。現在の研究は、この受容体の機能や相互作用の解明に重点が置かれており、今後はGITRをターゲットとした新たな治療法が発展することが期待されます。また、これらの治療法が実際に臨床でどのような効果を示すのか、さらなる検証が求められています。 腫瘍壊死因子受容体スーパーファミリーメンバー18(TNFRSF18)は、免疫系の調節に寄与する重要な受容体であり、がんや自己免疫疾患の治療に向けた新たなアプローチとして注目されています。本受容体の理解が深まることで、今後の医療においてより効果的な治療法が開発されることが期待されています。この受容体の研究は、免疫療法の進展に加えて、さまざまな疾患の新しい治療戦略に貢献する可能性があります。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer